These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 2398467

  • 1. In vitro release profile of estradiol transdermal therapeutic systems.
    Tymes NW, Shah VP, Skelly JP.
    J Pharm Sci; 1990 Jul; 79(7):601-2. PubMed ID: 2398467
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of mathematical models describing drug release from estradiol transdermal systems.
    Costa P, Sousa Lobo JM.
    Drug Dev Ind Pharm; 2003 Jan; 29(1):89-97. PubMed ID: 12602496
    [Abstract] [Full Text] [Related]

  • 3. HPLC-fluorescence determination of unconjugated estrogens in pharmaceuticals.
    Gatti R, Gioia MG, Di Pietra AM, Cavrini V.
    J Pharm Biomed Anal; 1998 Oct; 18(1-2):187-92. PubMed ID: 9863957
    [Abstract] [Full Text] [Related]

  • 4. Investigation of the release test method for the topical application of pharmaceutical preparations: release test of cataplasm including nonsteroidal anti-inflammatory drugs using artificial sweat.
    Shimamura T, Tairabune T, Kogo T, Ueda H, Numajiri S, Kobayashi D, Morimoto Y.
    Chem Pharm Bull (Tokyo); 2004 Feb; 52(2):167-71. PubMed ID: 14757999
    [Abstract] [Full Text] [Related]

  • 5. Acrylic resins as rate-controlling membranes in novel formulation of a nine-day 17beta-estradiol transdermal delivery system: in vitro and release modifier effect evaluation.
    Rafiee-Tehrani M, Safaii-Nikui N, Peteriet H, Beckert T.
    Drug Dev Ind Pharm; 2001 May; 27(5):431-7. PubMed ID: 11448050
    [Abstract] [Full Text] [Related]

  • 6. In vitro release profiles of clonidine transdermal therapeutic systems and scopolamine transdermal patches.
    Shah VP, Tymes NW, Skelly JP.
    Pharm Res; 1989 Apr; 6(4):346-51. PubMed ID: 2748524
    [No Abstract] [Full Text] [Related]

  • 7. Bioavailability of estradiol from two transdermal patches.
    Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C.
    Arzneimittelforschung; 1996 Mar; 46(3):307-10. PubMed ID: 8901155
    [Abstract] [Full Text] [Related]

  • 8. Plasma profiles of transdermal 17 beta-estradiol delivered by two different matrix patches. A four-way cross-over study in postmenopausal women.
    Rohr UD, Ehrly AM, Kuhl H.
    Arzneimittelforschung; 1997 Jun; 47(6):761-7. PubMed ID: 9239456
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
    Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C.
    Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
    [Abstract] [Full Text] [Related]

  • 10. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy.
    Gordon SF.
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 2):998-1004. PubMed ID: 7573298
    [Abstract] [Full Text] [Related]

  • 11. [Kinetics of a new patch for transdermal administration of 17 beta-estradiol].
    Rohr UD, Nauert C, Ehrly AM.
    Zentralbl Gynakol; 1995 Sep; 117(10):531-9. PubMed ID: 7491836
    [Abstract] [Full Text] [Related]

  • 12. Design and in vivo testing of 17 beta-estradiol-HP beta CD sublingual tablets.
    Fridriksdóttir H, Loftsson T, Gudmundsson JA, Bjarnason GJ, Kjeld M, Thorsteinsson T.
    Pharmazie; 1996 Jan; 51(1):39-42. PubMed ID: 8999433
    [Abstract] [Full Text] [Related]

  • 13. Real-time UV imaging of nicotine release from transdermal patch.
    Østergaard J, Meng-Lund E, Larsen SW, Larsen C, Petersson K, Lenke J, Jensen H.
    Pharm Res; 2010 Dec; 27(12):2614-23. PubMed ID: 20811931
    [Abstract] [Full Text] [Related]

  • 14. In-vitro and in-vivo characteristics of a modified-release double-pulse formulation for a water soluble drug.
    Avramoff A, Domb AJ.
    Int J Clin Pharmacol Ther; 2010 Apr; 48(4):250-8. PubMed ID: 20353746
    [Abstract] [Full Text] [Related]

  • 15. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch.
    Setnikar I, Rovati LC, Santoro A, Guillaume M, Mignot A, Renoux A, Gualano V.
    Arzneimittelforschung; 1999 Aug; 49(8):708-15. PubMed ID: 10483519
    [Abstract] [Full Text] [Related]

  • 16. New trends in transdermal technologies: development of the skin patch, Menorest.
    Marty JP.
    Int J Gynaecol Obstet; 1996 Mar; 52 Suppl 1():S17-20. PubMed ID: 8666122
    [Abstract] [Full Text] [Related]

  • 17. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
    Rovati LC, Schmid K, Giacovelli G, Bonn M, Setnikar I, Wolff F, Genazzani AR.
    Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
    [Abstract] [Full Text] [Related]

  • 18. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery.
    Baker VL.
    Obstet Gynecol Clin North Am; 1994 Jun; 21(2):271-97. PubMed ID: 7936545
    [Abstract] [Full Text] [Related]

  • 19. Controlled delivery of oestradiol-17-b from silastic implants: in vitro and in vivo evaluation.
    O'Sullivan M, Clancy JM, Roche JF, Corrigan OI.
    Eur J Drug Metab Pharmacokinet; 1991 Jun; Spec No 3():478-82. PubMed ID: 1820927
    [Abstract] [Full Text] [Related]

  • 20. Effects of 2-hydroxypropyl-beta-cyclodextrin on the aqueous solubility of drugs and transdermal delivery of 17 beta-estradiol.
    Loftsson T, Bodor N.
    Acta Pharm Nord; 1989 Jun; 1(4):185-94. PubMed ID: 2590460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.